AMAG Pharmaceuticals, Inc. Obtains US Commercial Rights to MuGard™ a Prescription Oral Rinse to Manage Oral Mucositis

Published: Jun 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., June 10, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has licensed the US commercial rights to MuGard™, a marketed product for the management of oral mucositis, from Access Pharmaceuticals, Inc. (OTCBB:ACCP). MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients developing the condition each year.

Help employers find you! Check out all the jobs and post your resume.

Back to news